NDA 022081 · Gilead
Letairis
Ambrisentan · Oral · Endothelin Receptor Antagonist
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Jun 15, 2007
Approved uses
3
Original approval plus efficacy supplements
Registered trials
66
23 Phase 3, 5 recruiting
FAERS reports
124,904
80,905 serious, 17,062 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY Letairis is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients, based on studies in animals [see Contraindications (4.1) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ] . Therefore, for females of reproductive potential, exclude pregnancy before the initiation of treatment with Letairis. Advise use of effective contraception before initiation, during treatment, and for one month after treatment with Letairis [see Dosage and Administration (2.2) Contraindications (4.1) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ]. When pregnancy is detected, discontinue Letairis as soon as possible ( 5.1 ). WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Based on animal data Letairis may cause fetal harm if...
What it is approved for
From the label in effect Jun 22, 2026.
Letairis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability [see Clinical Studies (14.2) ]. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ).
Mechanism: Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ET A and ET B , mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ET A are vasoconstriction and cell proliferation, while the predominant actions of ET B are vasodilation, antiproliferation, and ET-1 clearance. In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 2015 Supplement 33 · Efficacy OrphanLetterLabel
- Feb 15, 2012 Supplement 14 · Efficacy LetterLabel
- Jun 15, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelREMSLetter
2 products under this application
- LETAIRIS · AMBRISENTAN 5MG · TABLET, ORAL · Prescription · TE AB
- LETAIRIS · AMBRISENTAN 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ambrisentan" as an intervention, any sponsor and status, largest first.
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04273945 · 935 participants · Start Jun 30, 2020 · Primary completion Oct 7, 2025
Drug: Macitentan 10 mg; Macitentan 37.5 mg and 2 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 274 sites in all
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01178073 · 610 participants · Start Oct 1, 2010 · Primary completion Jul 31, 2014
Drug: ambrisentan; tadalafil · For: Hypertension, Pulmonary
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 143 sites in all
- (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPFPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT00768300 · 494 participants · Start Dec 2008 · Primary completion Feb 2011
Drug: Ambrisentan; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 185 sites in all
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and MechanismsPivotal-lookingCompleted
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT04393246 · 454 participants · Start Jul 3, 2020 · Primary completion Jun 1, 2022
Drug: EDP1815; Dapagliflozin and 1 more · For: COVID-19
Sites: Cambridge, United Kingdom
- Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial HypertensionPivotal-lookingStatus unknown
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
NCT04972656 · 420 participants (planned) · Start Sep 5, 2022 · Primary completion Dec 30, 2025
Drug: Ambrisentan; Placebo · For: Pulmonary Arterial Hypertension
Sites: Nanjing, China
- Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionPivotal-lookingNot yet recruiting
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
NCT06987097 · 410 participants (planned) · Start May 15, 2025 · Primary completion Feb 28, 2028
Drug: Ambrisentan; Placebo · For: Pulmonary Arterial Hypertension (PAH)
- A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00578786 · 383 participants · Start Feb 2004 · Primary completion Mar 2010
Drug: ambrisentan · For: Pulmonary Arterial Hypertension
Sites: Ciudad Autonoma de Buenos Aires, Argentina; Mar del Plata, Argentina; Munro, Argentina · 22 sites in all
- Comparison of Sequential to Initial Combination Therapy in PAHPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06968962 · 376 participants (planned) · Start May 14, 2025 · Primary completion May 2028
Drug: Tadalafil; Ambrisentan and 2 more · For: Pulmonary Arterial Hypertension (PAH)
Sites: Hangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea19,248
- death11,390
- headache10,875
- pneumonia7,286
- diarrhoea7,182
- fatigue6,670
- dizziness6,625
- nausea6,611
- fluid retention5,493
- malaise5,357
- cough4,658
- oedema peripheral4,223
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 67 |
| 2008 | 595 |
| 2009 | 883 |
| 2010 | 1,542 |
| 2011 | 2,831 |
| 2012 | 4,290 |
| 2013 | 9,021 |
| 2014 | 27,939 |
| 2015 | 9,463 |
| 2016 | 9,456 |
| 2017 | 9,414 |
| 2018 | 9,831 |
| 2019 | 8,079 |
| 2020 | 4,916 |
| 2021 | 4,551 |
| 2022 | 5,429 |
| 2023 | 5,506 |
| 2024 | 5,134 |
| 2025 | 3,775 |
| 2026 | 2,182 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Letairis (Ambrisentan)
2024 spending
$82.7M
Beneficiaries
1,309
6,082 claims
Per beneficiary
$63,163
$408.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $165,369,501 |
| 2021 | $125,766,283 |
| 2022 | $100,977,936 |
| 2023 | $88,566,586 |
| 2024 | $82,679,794 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, et al. · N Engl J Med 2015 · Multicenter Study, Randomized Controlled Trial
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
- Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.
Chen Q, Chen P, Liu L, et al. · J Am Soc Nephrol 2026 · Randomized Controlled Trial
- Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation.
Allan JM, Fox BM, Kasztan M, et al. · Clin Sci (Lond) 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.
Raghu G, Nathan SD, Behr J, et al. · Eur Respir J 2015 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
Li J, Yang ZY, Wang S, et al. · Front Cardiovasc Med 2022 · Systematic Review
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.